The company has not filed an annual or quarterly report since its Q3 FY2021 10-Q, filed Nov 4, 2021. Its latest SEC filing is a 15-12B from Dec 2, 2021.
10-Q for Q3 FY2021, filed Nov 4, 2021
The sections below describe the company as of the FY2020 annual report.
Developed therapeutics for serious and rare diseases, including REBLOZYL for certain blood disorders and candidates for pulmonary diseases.
10-K for FY2020, filed Feb 25, 2021We are a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat serious and rare…View ↗
We are actively developing our lead pulmonary program, sotatercept, for the treatment of patients with pulmonary arterial hypertension, or…View ↗
Our first commercial product, REBLOZYL® (luspatercept-aamt), is a first-in-class erythroid maturation agent designed to promote red blood…View ↗
Collaboration partners paid upfront fees, milestone payments when development events were reached, research and development reimbursements, and royalties on future product sales; the company also earned revenue from licenses and research services.
10-K for FY2020, filed Feb 25, 2021The Company has primarily generated revenue through collaboration, license and research arrangements, which are within the scope of ASC…View ↗
If the license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations…View ↗
The promises under the Company’s collaboration and license agreements generally include research and development services to be performed…View ↗
$92.5M
10-K for FY2020, filed Feb 25, 2021
$92.5M ↗
Worked with pharmaceutical collaboration partners, including Bristol Myers Squibb, through licensing, research and development, and commercialization agreements. Partners paid fees, milestone amounts, research reimbursements and royalties.
10-K for FY2020, filed Feb 25, 2021The Company has primarily generated revenue through collaboration, license and research arrangements, which are within the scope of ASC…View ↗
BMS is responsible for paying 100% of the development costs for all clinical trials for luspatercept-aamt. We may receive a maximum of…View ↗
Our first commercial product, REBLOZYL® (luspatercept-aamt), is a first-in-class erythroid maturation agent designed to promote red blood…View ↗
No. It lost $166M in .
10-K for FY2020, filed Feb 25, 2021
10-Q for Q3 FY2021, filed Nov 4, 2021
−$70.5MView ↗
8-K, filed Nov 22, 2021
Following the consummation of the Offer, on November 19, 2021, pursuant to the terms and conditions of the Merger Agreement and in…View ↗
Grew. Revenue grew 3.3x in 4 years, from $27.8M in to $92.5M in , about 35% a year.
REBLOZYL reaches commercialization
REBLOZYL went from a clinical-stage program to the company's first commercial product, approved for certain adults with beta-thalassemia or MDS.
10-K for FY2017, filed Feb 27, 2018 10-K for FY2020, filed Feb 25, 2021Luspatercept, our lead program, and sotatercept, are partnered with Celgene Corporation, or Celgene. Luspatercept is an erythroid…View ↗
Our first commercial product, REBLOZYL® (luspatercept-aamt), is a first-in-class erythroid maturation agent designed to promote red blood…View ↗
Therapeutic focus changes
The stated focus moves from hematologic, neuromuscular and pulmonary research to pulmonary and hematology commercialization, research and development.
10-K for FY2017, filed Feb 27, 2018 10-K for FY2020, filed Feb 25, 2021We are a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases.…View ↗
We focus and prioritize our commercialization, research and development activities within two key therapeutic areas: pulmonary and…View ↗
Competes with Novartis, Bluebird bio, Orchard Therapeutics, Sangamo BioSciences, Sanofi, CRISPR Therapeutics, Vertex, Agios Pharmaceuticals, Janssen Pharmaceuticals, BMS, Fibrogen, Onconova, Geron, Apogenix, Keros Therapeutics, Sierra Oncology, Gilead, Constellation Pharmaceuticals, Eli Lilly, and Pfizer
10-K for FY2020, filed Feb 25, 2021RBC transfusions, which are used to treat anemia in patients with beta-thalassemia, and iron chelation therapy, such as Novartis's oral…View ↗
Loading...
